0.167
price up icon39.17%   0.047
after-market After Hours: .17 0.003 +1.80%
loading
Oragenics Inc stock is traded at $0.167, with a volume of 270.65M. It is up +39.17% in the last 24 hours and down -14.32% over the past month. Oragenics, Inc. focuses on developing antibiotics against infectious diseases and treatments for oral mucositis. It is developing OG716, an antibiotic product candidate, which is in nonclinical testing for healthcare-associated infections, as well as other homolog antibiotic product candidates. The company is also developing AG013, which is in Phase II clinical trial for the treatment of oral mucositis in cancer patients. Its product candidates also comprise LPT3-04, a naturally occurring dietary substance for weight loss; and SMaRT Replacement Therapy, a topical treatment applied to the teeth to protect against tooth decay. Oragenics, Inc. has collaboration agreements with Intrexon Corporation and its subsidiary, Intrexon Actobiotics NV to develop AG013 as a potential treatment of oral mucositis for cancer patients. It also has license agreements with LPThera LLC to develop LPT3-04, a weight-loss product candidate; and Texas A&M University System for access to new homologs of the lantibiotic Mutacin 1140 (MU1140) and other lantibiotics, as well as holds licenses from the University of Florida Research Foundation, Inc. for MU1140 product candidates. The company was formerly known as Oragen, Inc. Oragenics, Inc. was founded in 1996 and is headquartered in Tampa, Florida.
See More
Previous Close:
$0.12
Open:
$0.27
24h Volume:
270.65M
Relative Volume:
59.99
Market Cap:
$3.59M
Revenue:
-
Net Income/Loss:
$-20.26M
P/E Ratio:
-0.0196
EPS:
-8.54
Net Cash Flow:
$-8.25M
1W Performance:
-12.11%
1M Performance:
-14.32%
6M Performance:
-47.81%
1Y Performance:
-91.73%
1-Day Range:
Value
$0.1629
$0.32
1-Week Range:
Value
$0.11
$0.32
52-Week Range:
Value
$0.11
$2.52

Oragenics Inc Stock (OGEN) Company Profile

Name
Name
Oragenics Inc
Name
Phone
813-286-7900
Name
Address
4902 Eisenhower Boulevard, Suite 125, Tampa, FL
Name
Employee
6
Name
Twitter
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
OGEN's Discussions on Twitter

Compare OGEN with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
OGEN
Oragenics Inc
0.167 4.12M 0 -20.26M -8.25M -8.54
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.93 25.76B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
445.43 114.53B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.415 40.54M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
84.10 6.44B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
490.81 65.13B 14.09B 4.50B 2.96B 39.28

Oragenics Inc Stock (OGEN) Latest News

pulisher
May 31, 2025

OGEN stock touches 52-week low at $0.12 amid sharp annual decline By Investing.com - Investing.com South Africa

May 31, 2025
pulisher
May 30, 2025

OGEN stock touches 52-week low at $0.12 amid sharp annual decline - Investing.com Australia

May 30, 2025
pulisher
May 29, 2025

Oragenics announces reverse stock split to begin June 3 By Investing.com - Investing.com South Africa

May 29, 2025
pulisher
May 28, 2025

Oragenics (OGEN) Announces One-for-Thirty Reverse Stock Split | - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Oragenics announces reverse stock split to begin June 3 - Investing.com Australia

May 28, 2025
pulisher
May 28, 2025

Oragenics Announces Reverse Stock Split to Boost Share Price - TipRanks

May 28, 2025
pulisher
May 28, 2025

Oragenics (OGEN) Announces One-for-Thirty Reverse Stock Split | OGEN Stock News - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Oragenics, Inc. Announces One-for-Thirty Reverse Stock Split - GlobeNewswire

May 28, 2025
pulisher
May 20, 2025

Oragenics Hosts Neurotrauma Medicine Webinar Presentation - TipRanks

May 20, 2025
pulisher
May 15, 2025

Oragenics (NYSE:OGEN) Earns Sell Rating from Analysts at StockNews.com - Defense World

May 15, 2025
pulisher
May 14, 2025

Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia - GlobeNewswire

May 14, 2025
pulisher
May 13, 2025

Oragenics (OGEN) Gains Approval for Phase II Trial of Neuroprote - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Oragenics gains Australia’s nod for concussion therapy trial - Investing.com Australia

May 13, 2025
pulisher
May 13, 2025

Oragenics gains Australia’s nod for concussion therapy trial By Investing.com - Investing.com Nigeria

May 13, 2025
pulisher
May 13, 2025

Oragenics, Inc. Announces Approval to Initiate Phase II Concussi - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia | OGEN Stock News - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Oragenics, Inc. to Host Management Update Webinar on May - GlobeNewswire

May 13, 2025
pulisher
May 12, 2025

Oragenics, Inc. to Host Management Update Webinar on May 20, 202 - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Oragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion Treatment Landscape, ONP-002 Clinical Program, and Strategic Vision | OGEN Stock News - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Oragenics, Inc. to Host Webinar on ONP-002 and Addressing Unmet Needs in Concussion Treatment - Nasdaq

May 12, 2025
pulisher
May 12, 2025

CSW Industrials Announces Date for Fiscal Fourth Quarter and Full Year 2025 Earnings Release Conference Call - The Manila Times

May 12, 2025
pulisher
May 10, 2025

Oragenics: Q1 Earnings Snapshot - New Haven Register

May 10, 2025
pulisher
May 07, 2025

Oragenics (NYSE:OGEN) Now Covered by StockNews.com - Defense World

May 07, 2025
pulisher
May 02, 2025

Oragenics Appoints New CEO and Amends Employment Terms By Investing.com - Investing.com Nigeria

May 02, 2025
pulisher
May 02, 2025

Oragenics Appoints New CEO and Amends Employment Terms - Investing.com Australia

May 02, 2025
pulisher
May 02, 2025

Oragenics Appoints Janet Huffman as CEO and CFO - TipRanks

May 02, 2025
pulisher
Apr 29, 2025

StockNews.com Initiates Coverage on Oragenics (NYSE:OGEN) - Defense World

Apr 29, 2025
pulisher
Apr 23, 2025

Oragenics, Inc. to Participate at the 15th Annual Traumatic Brai - GuruFocus

Apr 23, 2025
pulisher
Apr 23, 2025

Oragenics, Inc. to Participate at the 15th Annual Traumatic Brain Injury Conference | OGEN Stock News - GuruFocus

Apr 23, 2025
pulisher
Apr 23, 2025

Oragenics, Inc. to Present at the 15th Annual Traumatic Brain Injury Conference on Advances in mTBI Detection and Management - Nasdaq

Apr 23, 2025
pulisher
Apr 23, 2025

Oragenics, Inc. to Participate at the 15th Annual Traumatic Brain Injury Conference - GlobeNewswire

Apr 23, 2025
pulisher
Apr 21, 2025

Oragenics (NYSE:OGEN) Now Covered by Analysts at StockNews.com - Defense World

Apr 21, 2025
pulisher
Apr 10, 2025

Oragenics, Inc. Announces Health and Disability Ethics Committee - GuruFocus

Apr 10, 2025
pulisher
Apr 09, 2025

Oragenics, Inc. Announces Health and Disability Ethics Committee Submission for Phase IIa Concussion Trial - The Manila Times

Apr 09, 2025
pulisher
Apr 09, 2025

Oragenics Announces Health And Disability Ethics Committee Submission - MarketScreener

Apr 09, 2025
pulisher
Apr 08, 2025

Oragenics, Inc. Participates in the 3rd Nasal Formulation & Delivery Summit - GlobeNewswire

Apr 08, 2025

Oragenics Inc Stock (OGEN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$1.15
price up icon 6.48%
$31.19
price up icon 3.48%
$584.61
price up icon 1.98%
$306.09
price up icon 0.50%
$4.5994
price up icon 2.21%
$490.81
price up icon 0.11%
Cap:     |  Volume (24h):